BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 29880586)

  • 1. Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment.
    Sukumaran S; Watanabe N; Bajgain P; Raja K; Mohammed S; Fisher WE; Brenner MK; Leen AM; Vera JF
    Cancer Discov; 2018 Aug; 8(8):972-987. PubMed ID: 29880586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.
    Mohammed S; Sukumaran S; Bajgain P; Watanabe N; Heslop HE; Rooney CM; Brenner MK; Fisher WE; Leen AM; Vera JF
    Mol Ther; 2017 Jan; 25(1):249-258. PubMed ID: 28129119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer.
    Abate-Daga D; Lagisetty KH; Tran E; Zheng Z; Gattinoni L; Yu Z; Burns WR; Miermont AM; Teper Y; Rudloff U; Restifo NP; Feldman SA; Rosenberg SA; Morgan RA
    Hum Gene Ther; 2014 Dec; 25(12):1003-12. PubMed ID: 24694017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
    Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
    Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
    [No Abstract]   [Full Text] [Related]  

  • 5. Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice.
    Hillerdal V; Ramachandran M; Leja J; Essand M
    BMC Cancer; 2014 Jan; 14():30. PubMed ID: 24438073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology "UniCAR".
    Feldmann A; Arndt C; Bergmann R; Loff S; Cartellieri M; Bachmann D; Aliperta R; Hetzenecker M; Ludwig F; Albert S; Ziller-Walter P; Kegler A; Koristka S; Gärtner S; Schmitz M; Ehninger A; Ehninger G; Pietzsch J; Steinbach J; Bachmann M
    Oncotarget; 2017 May; 8(19):31368-31385. PubMed ID: 28404896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAR T-cell therapy for pancreatic cancer.
    DeSelm CJ; Tano ZE; Varghese AM; Adusumilli PS
    J Surg Oncol; 2017 Jul; 116(1):63-74. PubMed ID: 28346697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineered T cells for pancreatic cancer treatment.
    Katari UL; Keirnan JM; Worth AC; Hodges SE; Leen AM; Fisher WE; Vera JF
    HPB (Oxford); 2011 Sep; 13(9):643-50. PubMed ID: 21843265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells.
    Shum T; Omer B; Tashiro H; Kruse RL; Wagner DL; Parikh K; Yi Z; Sauer T; Liu D; Parihar R; Castillo P; Liu H; Brenner MK; Metelitsa LS; Gottschalk S; Rooney CM
    Cancer Discov; 2017 Nov; 7(11):1238-1247. PubMed ID: 28830878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Masked Chimeric Antigen Receptor for Tumor-Specific Activation.
    Han X; Bryson PD; Zhao Y; Cinay GE; Li S; Guo Y; Siriwon N; Wang P
    Mol Ther; 2017 Jan; 25(1):274-284. PubMed ID: 28129121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.
    Walker AJ; Majzner RG; Zhang L; Wanhainen K; Long AH; Nguyen SM; Lopomo P; Vigny M; Fry TJ; Orentas RJ; Mackall CL
    Mol Ther; 2017 Sep; 25(9):2189-2201. PubMed ID: 28676342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.
    Krenciute G; Prinzing BL; Yi Z; Wu MF; Liu H; Dotti G; Balyasnikova IV; Gottschalk S
    Cancer Immunol Res; 2017 Jul; 5(7):571-581. PubMed ID: 28550091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation.
    Bajgain P; Tawinwung S; D'Elia L; Sukumaran S; Watanabe N; Hoyos V; Lulla P; Brenner MK; Leen AM; Vera JF
    J Immunother Cancer; 2018 May; 6(1):34. PubMed ID: 29747685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM.
    Deng Z; Wu Y; Ma W; Zhang S; Zhang YQ
    BMC Immunol; 2015 Jan; 16(1):1. PubMed ID: 25636521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A regional approach for CAR T-cell therapy for mesothelioma: from mouse models to clinical trial.
    Mayor M; Zeltsman M; McGee E; Adusumilli PS
    Immunotherapy; 2016 May; 8(5):491-4. PubMed ID: 27140404
    [No Abstract]   [Full Text] [Related]  

  • 16. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.
    Beatty GL; Haas AR; Maus MV; Torigian DA; Soulen MC; Plesa G; Chew A; Zhao Y; Levine BL; Albelda SM; Kalos M; June CH
    Cancer Immunol Res; 2014 Feb; 2(2):112-20. PubMed ID: 24579088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy.
    Töpfer K; Cartellieri M; Michen S; Wiedemuth R; Müller N; Lindemann D; Bachmann M; Füssel M; Schackert G; Temme A
    J Immunol; 2015 Apr; 194(7):3201-12. PubMed ID: 25740942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR/Cas9-Mediated Knockout of DGK Improves Antitumor Activities of Human T Cells.
    Jung IY; Kim YY; Yu HS; Lee M; Kim S; Lee J
    Cancer Res; 2018 Aug; 78(16):4692-4703. PubMed ID: 29967261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
    Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
    Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.